Botox Injections Cut Migraine Days: Study from Jeddah

Research Summary

A recent study published in Pain Therapy highlights the benefits of onabotulinumtoxinA injections for chronic migraine sufferers in Jeddah, Saudi Arabia. Conducted at King Abdulaziz Medical City between 2016 and 2024, the study involved 133 patients, predominantly female (85%) and aged 40 or younger (56%). Remarkably, 67% of participants experienced 14 or fewer headache days in the three months following treatment. The median Migraine Disability Assessment Test score dropped from 28 (severe disability) to 8 (mild disability), with headache days decreasing from 60 to 10. Notably, 14% of patients faced side effects, mainly ptosis. This research underscores onabotulinumtoxinA’s efficacy as a preventive migraine therapy.

Study Details

📄 Title: Real-World Data on the Efficacy of OnabotulinumtoxinA Injections as Prophylactic Treatment for Migraine: A Retrospective Study from Jeddah, Saudi Arabia (2016-2024).

👥 Research Team: Attar A et al.

📚 Published In: Pain Ther

📅 Publication Date: 2025 Dec 16

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.